

Scientific Research Process

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 35066

Manuscript Type: ORIGINAL ARTICLE

Title: Prognostic value of lymphovascular invasion in Bismuth-Corlette Type IV hilar cholangiocarcinoma

Authors: Bei Li, Xian-Ze Xiong, Yong Zhou, Si-Jia Wu, Zhen You, Jiong Lu, Nan-Sheng Cheng

Correspondence to: Nan-Sheng Cheng, MD, PhD, Department of Biliary Surgery, West China Hospital of Sichuan University, No. 37 Guo Xue Xiang, Chengdu 610041, Sichuan Province, China.
nanshengcheng@yeah.net

1 What did this study explore?

Despite advances in surgical technique, the resection rate of Bismuth type IV hilar cholangiocarcinoma (HC) is increasing, the prognosis of patients with type IV HC is still unsatisfactory. The reasons for this remain unclear and seem to be complex and multifactorial. Lymphovascular invasion (LVI) has been shown associated with poorer prognosis in patients with various types of malignant tumors. The aim of the present study was to investigate whether LVI could predict the prognosis of type IV HC.

2 How did the authors perform all experiments?

The present study was not involved with experiments.

3 How did the authors process all experimental data?

The present study was not involved with experiment data.

4 How did the authors deal with the pre-study hypothesis?

Lymphovascular invasion (LVI) has been shown associated with poorer prognosis in patients with various types of malignant tumors. However, the relationship between LVI and HC was still unclear. Therefore, we retrospectively collected and analyzed the data of patients with type IV HC in our hospital to determine the relationship between LVI and prognosis of type IV HC

5 What are the novel findings of this study?

Our findings confirm that LVI could be used as a potential prognostic predictor for Bismuth type IV HC patients after radical resection. The results of the present study may bring a new factor for predicting post-operation survival of these patients.

Name: NanSheng Cheng

Signature: Nan Sheng Cheng **Date:** 2017. 7. 28